Trial · NCT06299098
Registered outcomes29
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 29
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of treatment-emergent adverse events (TEAEs) | Baseline to week 7 | Part A |
| Primary | Severity of TEAEs | Baseline to week 7 | Part A |
| Primary | Percent change in total fat mass | Baseline to week 26 | Part B |
| Primary | Percent change in total lean mass | Baseline to week 26 | Part B |
| Primary | Percent change in body weight | Baseline to week 26 | Part B |
| Primary | Percent change in total fat mass | Baseline to week 52 | Part C |
| Primary | Percent change in total lean mass | Baseline to week 52 | Part C |
| Primary | Percent change in body weight | Baseline to week 52 | Part C |
| Secondary | Concentrations of trevogrumab in serum over time | Up to 75 weeks | Part A, Part B, and Part C |
| Secondary | Percent change in total fat mass | Baseline to week 52 | Part B |
| Secondary | Percent change in total lean mass | Baseline to week 52 | Part B |
| Secondary | Percent change in body weight | Baseline to week 52 | Part B |
| Secondary | Change in waist circumference (cm) | Baseline to week 26 | Part B and Part C |
| Secondary | Change in waist circumference (cm) | Baseline to week 52 | Part C |
| Secondary | Percent change in fasting serum triglycerides | Baseline to week 26 | Part B |
| Secondary | Percent change in total cholesterol | Baseline to week 26 | Part B |
| Secondary | Percent change in Apolipoprotein B (Apo B) | Baseline to week 26 | Part B |
| Secondary | Percent change in Low-Density Lipoprotein Cholesterol (LDL-C) | Baseline to week 26 | Part B |
| Secondary | Concentrations of garetosmab in serum over time | Up to 75 weeks | Part B |
| Secondary | Incidence of anti-drug antibodies (ADA) to trevogrumab after repeated doses over time | Up to 75 weeks | Part B and Part C |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06299098/registered